NAT1 is included in the Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) [14], which has proven to be useful in identifying patients most likely to benefit from drug treatment [15]. This evidence concerns the gene NAT1 and breast carcinoma.